These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Hayashida M; Miki A; Honda S; Nakamura M Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640 [TBL] [Abstract][Full Text] [Related]
3. Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization. Shiragami C; Takasago Y; Osaka R; Kobayashi M; Ono A; Yamashita A; Hirooka K Am J Ophthalmol; 2018 Sep; 193():80-86. PubMed ID: 29940168 [TBL] [Abstract][Full Text] [Related]
4. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884 [TBL] [Abstract][Full Text] [Related]
5. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy. Hamzah F; Shinojima A; Mori R; Yuzawa M BMC Ophthalmol; 2014 Nov; 14():145. PubMed ID: 25421855 [TBL] [Abstract][Full Text] [Related]
6. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy. Kim YK; Ryoo NK; Woo SJ; Park KH Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of central serous chorioretinopathy in patients by age. Tanaka C; Iwahashi C; Komuku Y; Hozumi K; Mitarai K; Gomi F Jpn J Ophthalmol; 2021 Nov; 65(6):761-768. PubMed ID: 34387787 [TBL] [Abstract][Full Text] [Related]
8. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Gulkas S; Sahin O Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613 [TBL] [Abstract][Full Text] [Related]
10. Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy. Chen YC; Chen SN Br J Ophthalmol; 2020 Nov; 104(11):1561-1566. PubMed ID: 32051140 [TBL] [Abstract][Full Text] [Related]
11. Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy. Seo EJ; Um T; Yoon YH Clin Exp Ophthalmol; 2019 May; 47(4):505-512. PubMed ID: 30515936 [TBL] [Abstract][Full Text] [Related]
12. Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients. Park YG; Kang S; Kim M; Yoo N; Roh YJ Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1375-1383. PubMed ID: 28421342 [TBL] [Abstract][Full Text] [Related]
13. One-year follow-up of choroidal and macular thickness in acute non-treated central serous chorioretinopathy. Orduña-Azcona J; Pérez-Fernández E; Modamio L; De Manuel-Triantafilo S; Rodríguez-Hernández CF; Gili P Clin Exp Optom; 2023 Jan; 106(1):47-55. PubMed ID: 35157808 [TBL] [Abstract][Full Text] [Related]
14. Clinical course after the onset of choroidal neovascularization in eyes with central serous chorioretinopathy. Kim RY; Ma GJ; Park WK; Kim M; Park YG; Park YH Medicine (Baltimore); 2021 Aug; 100(34):e26980. PubMed ID: 34449466 [TBL] [Abstract][Full Text] [Related]
15. Natural Course of Pachychoroid Pigment Epitheliopathy. Yagi M; Miyake M; Mori Y; Hosoda Y; Takahashi A; Muraoka Y; Ueda-Arakawa N; Miyata M; Yamashiro K; Tamura H; Ooto S; Tsujikawa A Ophthalmol Sci; 2022 Dec; 2(4):100201. PubMed ID: 36531587 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Noh SR; Kang MS; Kim K; Kim ES; Yu SY Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247 [TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468 [TBL] [Abstract][Full Text] [Related]
18. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy. Okamoto M; Matsuura T; Ogata N Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):25-32. PubMed ID: 25559505 [TBL] [Abstract][Full Text] [Related]
19. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289 [TBL] [Abstract][Full Text] [Related]
20. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Jirarattanasopa P; Ooto S; Tsujikawa A; Yamashiro K; Hangai M; Hirata M; Matsumoto A; Yoshimura N Ophthalmology; 2012 Aug; 119(8):1666-78. PubMed ID: 22521082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]